Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SpectraCure P18 System and Verteporfin for Primary Localized Prostate Cancer
NCT06807359Phase 2Recruiting
- Sponsor
- SpectraCure
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 2
01
Overview
A Phase 2 trial of verteporfin in prostate cancer (PCa), sponsored by SpectraCure. Started Jan 2025; status: recruiting.
02
Drugs
verteporfin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06807359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06807359.